Skip to main content

Smith Stan's Form 4/A amendment

Amended

MAIA Biotechnology, Inc.MAIA · filed Mar 5, 2025

Accession no.
0001127602-25-008322
Filed
Mar 5, 2025
Trade date
Feb 24, 2025
Filing delay
9 days
Rule 10b5-1 plan
Not checked
Original filed
Feb 25, 2025

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $75.0K. It was filed 9 days after the trade.

This amendment replaces 0001127602-25-006574 (filed Feb 25, 2025).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Smith StanCIK 0001913199Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 24, 2025Common StockPPurchaseAcquired+50,000$1.50+$75,0001,180,060Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 24, 2025Common StockPPurchaseAcquired+50,000$1.87+$93,50050,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025.

F2

These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3

This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 3 to "February 24, 2025".

F4

These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the inital issuance date.

F5

These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read the full filing on SEC EDGAR (opens in a new tab)